ERC Belgium has asked the European Medicines Agency (EMA) to give conditional approval to its investigational anti-cancer vaccine Gliovac (ERC1671) for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. Gliovac, which the company also refers to as Sitoiganap, is an advanced form of immunotherapy made up of cancer cells and other tumoral components freshly collected from the patient (autologous tissue) and three or more other people with the same type of brain tumor (allogeneic tissue).…
You must be logged in to read/download the full post.
The post EMA Asked to Conditionally Approve Gliovac, Cancer Vaccine, for Recurrent Glioblastoma appeared first on BioNewsFeeds.